Pharma Industry Braces as Dems Hash Out Drug Price Package
September 23
Although House Democratic leaders recently suffered a setback when a trio of moderates in a key committee voted against a sweeping set of drug pricing reforms, health care policy experts tell AIS Health that the pharmaceutical industry has every reason to be worried about the prospect of government price controls becoming law.
As one Capitol Hill insider put it: “The drug lobby has never been as worked up and worried before as they are right now, and the reason is because there is an extreme likelihood that something is going to pass.”
© 2023 MMIT
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Peter Johnson Reporter, Health Plan Weekly and Radar on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile
